Novartis is discontinuing the development of JDQ443, a KRAS inhibitor for non-small cell lung cancer
https://seekingalpha.com/news/4111628-novartis-ending-development-phase-3-kras-lung-cancer-drug-report
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.